Envista (NYSE:NVST) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Envista (NYSE:NVST) issued its quarterly earnings results on Wednesday. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04, FiscalAI reports. Envista had a return on equity of 8.26% and a net margin of 22.01%. The firm had revenue of $691.50 million for the quarter, compared to analyst estimates of $688.74 million. During the same period last year, the company earned $0.32 EPS. The firm’s quarterly revenue was up 3.2% on a year-over-year basis.

Here are the key takeaways from Envista’s conference call:

• Envista reported 2.7% core sales growth, with adjusted EBITDA up 9% and adjusted EPS up 25%; gross and EBITDA margins expanded 20 and 80 basis points, respectively. Free cash flow conversion was 97%, and net leverage remained low at 0.6x.
• The company raised its 2026 outlook, now expecting 3.75%–4.25% core sales growth, 12.5%–14% adjusted EBITDA growth, and adjusted EPS of $1.54–$1.58. Management said the fourth-quarter outlook implies slightly negative core growth, partly reflecting four fewer selling days and continued macro uncertainty.
• China sales fell at a low-double-digit rate as orthodontics customers destocked ahead of VBP; management expects the process to bring substantial price reductions, including about 50% for orthodontics and 10%–15% for implants. It expects VBP to support volume and share gains, but acknowledged margin pressure in China.
• Spark grew at a high-single-digit rate, diagnostics and implants each grew mid-single digits, and Envista said it continued to gain share in diagnostics. Management highlighted a strong new-product pipeline and said broader commercialization of recent launches will be a key growth priority for 2027.

Envista Price Performance

Envista stock traded up $0.06 during trading hours on Friday, hitting $25.02. 1,581,222 shares of the company traded hands, compared to its average volume of 2,950,749. Envista has a 1-year low of $18.77 and a 1-year high of $30.42. The company has a quick ratio of 2.07, a current ratio of 2.43 and a debt-to-equity ratio of 0.47. The firm has a market cap of $4.02 billion, a P/E ratio of 6.47, a P/E/G ratio of 1.38 and a beta of 0.94. The firm’s 50-day simple moving average is $24.43 and its two-hundred day simple moving average is $25.73.

Insider Activity

In other news, SVP Mischa Reis sold 8,000 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $27.50, for a total value of $220,000.00. Following the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. The trade was a 22.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on NVST. Mizuho set a $29.00 price target on Envista in a research note on Thursday, August 6th. Morgan Stanley set a $23.00 target price on shares of Envista in a research note on Thursday, August 6th. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on Envista in a research note on Thursday, September 3rd. Zacks Research downgraded shares of Envista from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Envista in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $29.00.

Envista News Roundup

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Envista reported Q3 adjusted earnings of $0.40 per share, above the $0.36 consensus, while revenue of $691.5 million also exceeded estimates and grew 3.2% year over year. The company raised its 2026 earnings outlook, citing pricing and productivity gains—factors that could support investor confidence. Q3 guidance and risks
• Positive Sentiment: UBS raised its price target from $27 to $29, indicating potential upside from the quoted share price, though it retained a neutral rating. UBS price target
• Neutral Sentiment: Recent valuation coverage described NVST as potentially undervalued based on earnings guidance, while another article highlighted its momentum ranking. These are investment assessments rather than new company developments. Valuation analysis Momentum analysis
• Negative Sentiment: China’s procurement reforms could pressure margins as Envista moves into 2027, tempering the benefit of its higher 2026 outlook. China risks

Envista Company Profile

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.